US SEC Trading Suspension Halt Orders — July 06, 2026

Received a second 180-day compliance extension to December 28, 2026, indicating Nasdaq's willingness to grant leniency; however, the company must complete a reverse stock split by December 14, 2026, if needed. No insider buying reported, suggesting management lacks conviction in organic recovery.

Failed the $35 million MVLS requirement; market value likely below $35 million as of June 29, 2026. The company may attempt to boost stockholders' equity to $2.5 million as an alternative path, but no insider purchases or capital allocation actions have been disclosed.

Stockholders' equity of only $144,000 vs. $2.5 million requirement—a 94% deficiency. The company has until October 28, 2026, to file a pro forma balance sheet evidencing a completed transaction. No insider buying or capital infusion announced, signaling extreme distress.

None have reported insider buying, dividend increases, or buyback programs in the enriched data, indicating a lack of management confidence and poor capital allocation flexibility.

The reverse stock split catalyst is binary—if executed by December 14, 2026, it could temporarily boost share price above $1, but history shows splits often lead to further declines. No guidance on revenue or earnings was provided. [NEUTRAL/BEARISH]

The 180-day grace period provides a window for potential M&A or equity infusion, but no forward-looking guidance or transaction details were disclosed. The stock continues trading under CTSO, but delisting risk is high.

The compliance plan was accepted by Nasdaq, but the company must demonstrate compliance by its next periodic report (likely Q3 2026) or face delisting. No operational metrics or revenue trends were provided to assess turnaround potential.

Zero insider transactions across all three filings—no purchases, sales, or pledges. This is a strong bearish signal, as insiders typically buy when they see value or a catalyst.

Stockholders' equity of $144,000 is 94% below the $2.5 million minimum, the most severe deficiency among the three. If no transaction is completed by October 28, 2026, delisting is almost certain.

Failure to maintain $35 million MVLS; if the stock price continues to decline, the company may not regain compliance within 180 days. No alternative plan disclosed beyond equity increase.

Second extension granted, but if the reverse stock split is not approved or executed by December 14, 2026, delisting follows. No assurance of compliance given.

The complete absence of insider purchases across all filings suggests management sees no near-term value or catalyst, increasing the probability of delisting.

The filing lacks any period-over-period revenue or margin comparisons, making it impossible to assess operational health. The equity deficiency implies negative retained earnings and likely operating losses.

No revenue, earnings, or operational guidance was provided, leaving investors blind to any potential recovery. The MVLS failure suggests market cap erosion, possibly due to poor fundamentals.

If a reverse split is executed, existing shareholders face dilution and potential further price decline post-split, as is common with distressed micro-caps.

CISO and CytoSorbents share a December 28, 2026 deadline, while Polar Power's is October 28, 2026. A cluster of delistings could create negative sentiment for the entire micro-cap space.

The October 28 deadline forces the company to complete a transaction (e.g., equity raise, debt conversion, or asset sale). If a credible investor or strategic partner emerges, the stock could re-rate. However, no insider buying suggests low probability.

If the company announces a positive catalyst (e.g., FDA approval, partnership, or equity infusion) that boosts market cap above $35 million for 10 consecutive days, the stock could rally. No such catalyst is currently identified.

If the reverse split is announced and executed, short-term traders may attempt to capture a post-split bounce. However, the risk of further decline is high, and no insider buying supports this.

All three stocks are micro-caps with low liquidity and high short interest (likely). Any positive news (e.g., compliance regained) could trigger a short squeeze. Monitor short interest data.

If the company files a pro forma balance sheet showing compliance by October 28, it could signal a successful restructuring or capital infusion, creating a buying opportunity.

The company may increase stockholders' equity to $2.5 million, which could be achieved via a rights offering or private placement. If priced attractively, investors could participate.

Three companies in this digest face delisting for different reasons (bid price, market value, equity), highlighting a systemic risk for micro-cap issuers with weak balance sheets and no insider support. Aggregate equity deficiency across Polar Power alone is $2.36 million.

Across all three filings, there are zero insider transactions (buys, sells, pledges). This is a powerful negative signal, as insiders typically buy when they see a path to compliance or value.

None of the companies have dividends, buybacks, or stock splits (other than CISO's potential reverse split). This indicates severe financial constraints and inability to return capital to shareholders.

Two of the three companies (CISO and CytoSorbents) share a December 28, 2026 deadline, while Polar Power's is October 28. This creates a potential wave of delistings that could impact investor sentiment for the broader micro-cap and small-cap space.

None of the filings provide revenue, earnings, or operational guidance, leaving investors without any visibility into future performance. This amplifies uncertainty and risk.

October 28, 2026 deadline to file pro forma balance sheet evidencing compliance. Watch for any 8-K filing announcing a transaction (equity raise, debt conversion, or asset sale).

December 14, 2026 deadline to complete reverse stock split if needed. Watch for shareholder vote on reverse split and any Nasdaq compliance update.

December 28, 2026 deadline to regain $35 million MVLS for 10 consecutive days. Monitor stock price and market cap daily; any positive news (partnership, FDA, earnings) could trigger compliance.

Monitor for any insider buying activity—if insiders start purchasing shares, it could signal a turnaround or imminent catalyst. Currently, no insider activity is reported.

Next periodic report (likely Q3 2026) due around November 2026; if it shows compliance, delisting risk drops. Watch for filing date.

Any announcement of an equity offering or strategic transaction to boost stockholders' equity. Watch for 8-K filings.

Stock price movement relative to $1 bid price; if it stays above $1 organically, reverse split may not be needed. Monitor daily.